PPARA and cardiovascular disorder: Until now, only PPARα agonists (e.g., fibrates) have been in clinical use for lipid lowering, the prevention of atherosclerosis, and cardiovascular disease [15,16], while PPARγ agonists (e.g., thiazolidinediones) lower glucose by increasing insulin sensitivity, mainly in skeletal muscle and adipose tissue [17].